Source: Interpol By Exec-Edge The government of Uzbekistan’s ongoing investigation into the attempted murder of former presidential press secretary Komil Allamjonov has widened to include two Russian men with ties to Chechnya. Last week, Uzbekistan charged Bislan Rasaev, 36, and...

By Karen Roman March Biosciences said it elected Peter Olagunju as chair of its Board of Directors, following a $28.4 million Series A financing the company secured for its lead cancer therapy. Mr. Olagunju has over 20 years of experience...

By Daniella Parra MOBILion Systems said it partnered with Dr. Oliver Schmitz of the University of Duisburg-Essen, known for his expertise in multidimensional chromatography and ion source development, to integrate its technology. This collaboration focuses on advancing multiomics applications, particularly...

Tech Edge hosted a fireside chat on Dec. 10 at Nasdaq MarketSite with Roey Eliyahu, Chief Executive Officer and co-founder of Salt Security. The in-person interview was joined by Editor-at-Large Jarrett Banks and they discussed the API security market and Salt’s distinct...

Tech Edge hosted a fireside chat on Dec. 10 at Nasdaq MarketSite with Jeff Winter, Chief Marketing Officer of Octus. The in-person interview was joined by Editor-in-Chief John Jannarone and they discussed Reorg’s recent rebranding to Octus, why the company is the...

By Karen Roman Agendia, Inc. said it will present data to assess treatment decisions on patients with early-stage breast cancer at the San Antonio Breast Cancer Symposium 2024. The studies will show how genomic testing can predict patients’ response to chemotherapy,...

By Karen Roman Institutional target allocations to real estate are set to decline in 2025 after holding steady at 10.8% for two years, according to the Institutional Real Estate Allocations Monitor published by Hodes Weill and Cornell University. Signs of...

By Karen Roman Agendia, Inc. said it will present MammaPrint’s ability to predict chemotherapy benefit in patients with early-stage breast cancer at the San Antonio Breast Cancer Symposium 2024. “This study highlights the ability of MammaPrint to provide a comprehensive...

By Karen Roman Candel Therapeutics, Inc. (Nasdaq: CADL) said Phase 3 of its prostate cancer candidate CAN-2409 showed an upgrade in disease-free survival in intermediate-to-high-risk patients. “We look forward to working with the FDA, as a next step, to seek...

By Karen Roman Biopharma company Lisata Therapeutics, Inc. (Nasdaq: LSTA) said it finished patient enrollment for the next stage of its CENDIFOX trial. The study will assess the safety and effects of combining certepetide, Lisata’s cyclic peptide candidate, with FOLFIRINOX-based...